Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease

Metastatic breast cancer is usually diagnosed after becoming symptomatic, at which point it is rarely curable. Cell‐free circulating tumor DNA (ct DNA ) contains tumor‐specific chromosomal rearrangements that may be interrogated in blood plasma. We evaluated serial monitoring of ct DNA for earlier detection of metastasis in a retrospective study of 20 patients diagnosed with primary breast cancer and long follow‐up. Using an approach combining low‐coverage whole‐genome sequencing of primary tumors and quantification of tumor‐specific rearrangements in plasma by droplet digital PCR , we identify for the first time that ct DNA monitoring is highly accurate for postsurgical discrimination between patients with (93%) and without (100%) eventual clinically detected recurrence. ct DNA ‐based detection preceded clinical detection of metastasis in 86% of patients with an average lead time of 11 months (range 0–37 months), whereas patients with long‐term disease‐free survival had undetectable ct DNA postoperatively. ct DNA quantity was predictive of poor survival. These findings establish the rationale for larger validation studies in early breast cancer to evaluate ct DNA as a monitoring tool for early metastasis detection, therapy modification, and to aid in avoidance of overtreatment.